Document is current
Any future updates will be listed below
-
Authors
Venner, Jeffery M.
McGovern, Dermot P.B.
Abreu, Maria T.
-
Funding
Funding for this research was provided by:
Cedars-Sinai Medical Center
- License Information
-
More Information
Article History
Received: 11 July 2025
Accepted: 28 August 2025
First Online: 13 November 2025
Declarations
:
: No ethics approval was required.
: Dr. Abreu is a consultant or on the advisory board for AbbVie Inc., Alimentiv Inc., Amgen, Bristol Myers Squibb, Eli Lilly and Company, Genetech, Gilead Sciences, Janssen Pharmaceuticals, Pfizer Pharmaceutical, Takeda Pharmaceuticals, and UCB Pharma. Dr. McGovern declares consulting fees from Prometheus Biosciences, Takeda, Pfizer, and Prometheus Laboratories, and holds patents for anti-TL1A therapy in IBD. Dr. Venner has no relevant financial or nonfinancial interests to disclose.
